US Throws Drug Pricing Weight Around, But Still Depends On Pharma Decisions
US may have substantial drug purchasing muscle, as evident in latest CMS proposal to reform Medicare Part B, but still needs pharma to force prices down.
You may also be interested in...
Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.
US FDA Commissioner Gottlieb says common diseases need new treatments and argues streamlining trials may pique industry interest.
Centers for Medicare and Medicaid Services asks whether private actions under Lanham Act are sufficient for enforcement, or whether participation in federal health programs should be conditioned on including drug list prices in direct-to-consumer TV commercials; comment deadline on controversial proposed rule is Dec. 17.